<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial</h1>
      <div class="meta">2025-09-08 17:25:58+00:00 UTC</div>
      <ul>
        <li>Pharmaceuticals industry, which had an 11.5% decline.</li>
        <li>market, which gained 20.8% over the past year, and the U.S.</li>
        <li>This announcement likely played a key role in the company’s 16% share price rise over the past month.</li>
        <li>Over the past five years, Eli Lilly&#x27;s total shareholder return, inclusive of share price appreciation and dividends, reached 416.18%, demonstrating significant longer-term performance.</li>
        <li>Currently, the company&#x27;s shares trade at US$727.21, showing a considerable discount to the consensus price target of US$891.62, indicating potential room for upward correction should these growth drivers effectively mate</li>
        <li>We&#x27;ve spotted 2 weaknesses for Eli Lilly you should be aware of, and 1 of them is a bit unpleasant.</li>
        <li>This article by Simply Wall St is general in nature.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/eli-lilly-lly-announces-promising-results-for-jaypirca-in-cll-phase-3-trial/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/news/eli-lilly-lly-announces-promising-172558054.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=Eli+Lilly+%28LLY%29+Announces+Promising+Results+For+Jaypirca+In+CLL+Phase+3+Trial%0A%E2%80%A2+Pharmaceuticals+industry%2C+which+had+an+11.5%25+decline.%0A%E2%80%A2+market%2C+which+gained+20.8%25+over+the+past+year%2C+and+the+U.S.%0A%E2%80%A2+This+announcement+likely+played+a+key+role+in+the+compan%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Feli-lilly-lly-announces-promising-results-for-jaypirca-in-cll-phase-3-trial%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
